MX350862B - Acidos de piperidinil naftilacetico. - Google Patents

Acidos de piperidinil naftilacetico.

Info

Publication number
MX350862B
MX350862B MX2014006468A MX2014006468A MX350862B MX 350862 B MX350862 B MX 350862B MX 2014006468 A MX2014006468 A MX 2014006468A MX 2014006468 A MX2014006468 A MX 2014006468A MX 350862 B MX350862 B MX 350862B
Authority
MX
Mexico
Prior art keywords
compounds
formula
piperidinyl
naphthylacetic acids
receptor
Prior art date
Application number
MX2014006468A
Other languages
English (en)
Other versions
MX2014006468A (es
Inventor
So Sung-Sau
Lin Tai-An
Sidduri Achyutharao
Firooznia Fariborz
Mertz Eric
Wright Tilley Jefferson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014006468A publication Critical patent/MX2014006468A/es
Publication of MX350862B publication Critical patent/MX350862B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención se refiere a los compuestos de fórmula (I): y sales farmacéuticamente aceptables de los mismos, en la que R1, R2, R3 y X son definidos en la descripción detallada y las reivindicaciones. Además, la presente invención se refiere a métodos de fabricación y uso de los compuestos de fórmula (I), así como composiciones farmacéuticas que contienen tales compuestos. Los compuestos de fórmula (I) son antagonistas o agonistas parciales en el receptor CRTH2 y pueden ser útiles en el tratamiento de enfermedades y trastornos asociados con ese receptor, tales como asma.
MX2014006468A 2011-12-12 2012-12-10 Acidos de piperidinil naftilacetico. MX350862B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161569313P 2011-12-12 2011-12-12
PCT/EP2012/074882 WO2013087544A1 (en) 2011-12-12 2012-12-10 Piperidinyl naphthylacetic acids

Publications (2)

Publication Number Publication Date
MX2014006468A MX2014006468A (es) 2014-09-01
MX350862B true MX350862B (es) 2017-09-19

Family

ID=47427287

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006468A MX350862B (es) 2011-12-12 2012-12-10 Acidos de piperidinil naftilacetico.

Country Status (11)

Country Link
US (1) US8691993B2 (es)
EP (1) EP2791111B1 (es)
JP (1) JP6154397B2 (es)
KR (1) KR20140103319A (es)
CN (1) CN103958468B (es)
BR (1) BR112014013958A2 (es)
CA (1) CA2855940A1 (es)
HK (1) HK1200453A1 (es)
MX (1) MX350862B (es)
RU (1) RU2628083C2 (es)
WO (1) WO2013087544A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 그의 용도
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CA2889922C (en) 2012-11-06 2016-01-19 Evolution Engineering Inc. Fluid pressure pulse generator and method of using same
CA2894621C (en) 2012-12-17 2019-04-30 Evolution Engineering Inc. Mud pulse telemetry apparatus with a pressure transducer and method of operating same
CA2895346C (en) 2012-12-17 2018-10-23 Evolution Engineering Inc. Downhole telemetry signal modulation using pressure pulses of multiple pulse heights
US10753201B2 (en) 2012-12-17 2020-08-25 Evolution Engineering Inc. Mud pulse telemetry apparatus with a pressure transducer and method of operating same
US9670774B2 (en) 2014-06-27 2017-06-06 Evolution Engineering Inc. Fluid pressure pulse generator for a downhole telemetry tool
US9631487B2 (en) 2014-06-27 2017-04-25 Evolution Engineering Inc. Fluid pressure pulse generator for a downhole telemetry tool
US9631488B2 (en) 2014-06-27 2017-04-25 Evolution Engineering Inc. Fluid pressure pulse generator for a downhole telemetry tool
US20210261495A1 (en) * 2018-06-29 2021-08-26 Ergon Pharmaceuticals, LLC Compositions and methods of using itaconic acid derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443462A (en) * 1979-08-06 1984-04-17 Merrell Dow Pharmaceuticals Inc. Antipsychotic 4-(naphthalenyloxy)piperidine derivatives
UA90706C2 (ru) * 2005-02-24 2010-05-25 Милленниум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
ES2625378T3 (es) * 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
JP2009539881A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Dp−2アンタゴニストとしての置換フェニル酢酸
WO2010045276A2 (en) * 2008-10-16 2010-04-22 Cara Therapeutics, Inc. Azabenzimidazolones
US8621184B1 (en) 2008-10-31 2013-12-31 Netapp, Inc. Effective scheduling of producer-consumer processes in a multi-processor system
MX2011005120A (es) * 2008-11-17 2011-05-30 Hoffmann La Roche Acidos naftilaceticos.
CA2739725A1 (en) * 2008-11-17 2010-05-20 F. Hoffmann-La Roche Ag Naphthylacetic acids used as crth2 antagonists or partial agonists

Also Published As

Publication number Publication date
WO2013087544A1 (en) 2013-06-20
CA2855940A1 (en) 2013-06-20
JP2015504863A (ja) 2015-02-16
CN103958468B (zh) 2017-03-01
BR112014013958A8 (pt) 2017-06-13
HK1200453A1 (en) 2015-08-07
JP6154397B2 (ja) 2017-06-28
US8691993B2 (en) 2014-04-08
CN103958468A (zh) 2014-07-30
EP2791111B1 (en) 2017-01-18
KR20140103319A (ko) 2014-08-26
RU2628083C2 (ru) 2017-08-14
RU2014127143A (ru) 2016-02-10
US20130150407A1 (en) 2013-06-13
BR112014013958A2 (pt) 2017-06-13
MX2014006468A (es) 2014-09-01
EP2791111A1 (en) 2014-10-22

Similar Documents

Publication Publication Date Title
MX350862B (es) Acidos de piperidinil naftilacetico.
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
WO2010018109A3 (en) Substituted aminotetralines
WO2010018113A3 (en) Bi-aryl aminotetralines
WO2010018112A3 (en) Monoaryl aminotetralines
PH12014502363A1 (en) N-aryltriazole compounds as lpar antagonists
PH12014502789A1 (en) N-alkyltriazole compounds as lpar antagonists
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MD20140002A2 (ro) Indazoli
TN2014000254A1 (en) Substituted triazolopyridines and their use as ttk inhibitors
MX2010001486A (es) Derivados de tetrahidropiridin carboxamida como antagonistas de trpvl.
PH12015500457A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
EA023861B3 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
IN2012DN03337A (es)
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
SG195106A1 (en) Trpv4 antagonists
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
IN2014MN02380A (es)
MX2020005735A (es) Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida.
TN2013000529A1 (en) Trpm8 antagonists and their use in treatments
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
UA109867C2 (ru) Замещенные соединения пиразола как антагонисты рецепторов лизофосфатидной кислоты (lpar)
MX2013001234A (es) Derivados deuterados de tandospirona como agonistas del receptor 5-hidroxitriptamina 1a.
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
IN2012DN00763A (es)

Legal Events

Date Code Title Description
FG Grant or registration